BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8157256)

  • 1. Lipoprotein analysis in transgenic mice expressing human apolipoprotein (apo) A-I and apo C III: use of micromethods in analysis of lipoprotein system in mice.
    Ito Y
    Hokkaido Igaku Zasshi; 1994 Mar; 69(2):312-26. PubMed ID: 8157256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human apoA-I/C-III/A-IV gene cluster transgenic rabbits: effects of a high-cholesterol diet.
    Recalde D; Baroukh N; Viglietta C; Prince S; Verona J; Vergnes L; Pidoux J; Nazeem Nanjee M; Brites F; Ochoa A; Castro G; Zakin MM; Miller NE; Marie Houdebine L
    FEBS Lett; 2004 Aug; 572(1-3):294-8. PubMed ID: 15304365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
    Ebara T; Ramakrishnan R; Steiner G; Shachter NS
    J Clin Invest; 1997 Jun; 99(11):2672-81. PubMed ID: 9169497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperexpression of N-acetylglucosaminyltransferase-III in liver tissues of transgenic mice causes fatty body and obesity through severe accumulation of Apo A-I and Apo B.
    Lee J; Song EY; Chung TW; Kang SK; Kim KS; Chung TH; Yeom YI; Kim CH
    Arch Biochem Biophys; 2004 Jun; 426(1):18-31. PubMed ID: 15130779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
    Berthou L; Duverger N; Emmanuel F; Langouët S; Auwerx J; Guillouzo A; Fruchart JC; Rubin E; Denèfle P; Staels B; Branellec D
    J Clin Invest; 1996 Jun; 97(11):2408-16. PubMed ID: 8647932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation.
    Navarro MA; Carpintero R; Acín S; Arbonés-Mainar JM; Calleja L; Carnicer R; Surra JC; Guzmán-García MA; González-Ramón N; Iturralde M; Lampreave F; Piñeiro A; Osada J
    Cytokine; 2005 Jul; 31(1):52-63. PubMed ID: 15878672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of expressed human apolipoprotein AI on plasma high density lipoprotein level in transgenic mice].
    Li H; Gu S; She M
    Zhonghua Yi Xue Za Zhi; 1998 Jul; 78(7):531-3. PubMed ID: 10923465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.
    Gautier T; Masson D; Jong MC; Pais de Barros JP; Duverneuil L; Le Guern N; Deckert V; Dumont L; Bataille A; Zak Z; Jiang XC; Havekes LM; Lagrost L
    Biochem J; 2005 Jan; 385(Pt 1):189-95. PubMed ID: 15339254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of induced atherosclerosis in h-apo AI transgenic mice by overexpression of human apo AI in the aortic wall.
    Li H; Gu S; Cao X; Wang Z; She M
    Chin Med J (Engl); 2000 Jul; 113(7):657-61. PubMed ID: 11776042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a hypertriglyceridemic transgenic miniature pig model expressing human apolipoprotein CIII.
    Wei J; Ouyang H; Wang Y; Pang D; Cong NX; Wang T; Leng B; Li D; Li X; Wu R; Ding Y; Gao F; Deng Y; Liu B; Li Z; Lai L; Feng H; Liu G; Deng X
    FEBS J; 2012 Jan; 279(1):91-9. PubMed ID: 22023023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis.
    Vergnes L; Baroukh N; Ostos MA; Castro G; Duverger N; Nanjee MN; Najib J; Fruchart JC; Miller NE; Zakin MM; Ochoa A
    Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):2267-74. PubMed ID: 11031214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.
    Kypreos KE
    Biochemistry; 2008 Sep; 47(39):10491-502. PubMed ID: 18767813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
    Jong MC; Havekes LM
    Int J Tissue React; 2000; 22(2-3):59-66. PubMed ID: 10937355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
    Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
    Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.
    Jong MC; van Dijk KW; Dahlmans VE; Van der Boom H; Kobayashi K; Oka K; Siest G; Chan L; Hofker MH; Havekes LM
    Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):281-7. PubMed ID: 10024503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies.
    Fredrikson GN; Björkbacka H; Söderberg I; Ljungcrantz I; Nilsson J
    J Intern Med; 2008 Dec; 264(6):563-70. PubMed ID: 18783480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of apolipoprotein CIII increases and CETP reverses diet-induced obesity in transgenic mice.
    Salerno AG; Silva TR; Amaral ME; Alberici LC; Bonfleur ML; Patrício PR; Francesconi EP; Grassi-Kassisse DM; Vercesi AE; Boschero AC; Oliveira HC
    Int J Obes (Lond); 2007 Oct; 31(10):1586-95. PubMed ID: 17471296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between apolipoprotein C-III concentrations and high-density lipoprotein subclass distribution.
    Tian L; Wu J; Fu M; Xu Y; Jia L
    Metabolism; 2009 May; 58(5):668-74. PubMed ID: 19375590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.